D
David R. Gandara
Researcher at University of California, Davis
Publications - 725
Citations - 45633
David R. Gandara is an academic researcher from University of California, Davis. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 84, co-authored 685 publications receiving 40321 citations. Previous affiliations of David R. Gandara include National Institutes of Health & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
2007 Highlights from: the 43rd Annual Meeting of the American Society of Clinical Oncology Chicago, IL; June 2007
Journal Article
Enhancing the anticancer activity of paclitaxel through cyclin-dependent kinase inhibition
TL;DR: The hypothesis that an accelerated exit from taxane-induced M-phase arrest, via inhibition of the Cyclin B-Cdk1 complex, increases the anticancer activity of taxanes is hypothesized.
Journal ArticleDOI
MA16.03 Global RET Registry (GLORY): Activity of RET-Directed Targeted Therapies in RET-Rearranged Lung Cancers
Oliver Gautschi,Julie Milia-Baron,Thomas Filleron,Jürgen Wolf,David P. Carbone,Dwight H. Owen,D. Ross Camidge,Vighesh Narayanan,Robert C. Doebele,Benjamin Besse,Jordi Remon,Pasi A. Jänne,Mark M. Awad,Nir Peled,Chul-Cho Byoung,Daniel D. Karp,Michael Van Den Heuvel,Heather A. Wakelee,Joel W. Neal,Tony Mok,James Chih-Hsin Yang,Sai-Hong Ou,Georg Pall,Patrizia Froesch,Gérard Zalcman,David R. Gandara,Jonathan W. Riess,Vamsidhar Velcheti,Kristin Zeidler,Joachim Diebold,Martin Früh,Sebastian Michels,Isabelle Monnet,Sanjay Popat,Rafael Rosell,Niki Karachaliou,Sacha I. Rothschild,Jin-Yuan Shih,Arne Warth,Thomas Muley,Florian Cabillic,Julien Mazieres,Alexander Drilon +42 more
Journal ArticleDOI
Relevance of platinum (plat) sensitivity status in previously treated extensive-stage small cell lung cancer (ES-SCLC) in the modern era: A patient level analysis of SWOG trials.
Primo N. Lara,James C. Moon,Mary W. Redman,Karen Kelly,Jeffrey Warren Allen,Barbara J. Gitlitz,Philip C. Mack,David R. Gandara +7 more
TL;DR: A large number of ES-SCLC patients with progressive disease following plat-based chemo are traditionally categorized as plat-sensitive or refractory, but this practice arose from seminal observations in the early 1980s of worse survival inRefractory pts.
Journal ArticleDOI
Prevalence and association of ARID1A with driver alterations and immune checkpoint inhibitor (ICPi) biomarkers in cell-free circulating tumor DNA (ctDNA) from 27,000 non-small cell lung cancer (NSCLC) patients.
David R. Gandara,Caroline M. Weipert,Jennifer Saam,Jonathan W. Riess,Heinz-Josef Lenz,Razelle Kurzrock +5 more
TL;DR: This data indicates that the tumor suppressor gene ARID1A is associated with high anti-tumor immunity and may have value as a predictive biomarker for response to ICPi therapy in NS patients.